ArticleCentral European journal of urology2024
Mean platelet volume to lymphocyte ratio as an inflammatory marker associated with high-grade recurrence and progression of non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guérin.
Article in Central European journal of urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: To assess the value of a novel inflammatory marker involving the ratio between mean platelet volume and lymphocyte counts (MPVL) in the prediction of high-grade recurrence-free survival (HG RFS) and progression-free survival (PFS) in patients with non-muscle-invasive bladder cancer (NMIBC) treated with adjuvant Bacillus Calmette-Guérin (BCG) therapy. Material and methods: In this retrospective, single tertiary centre study the medical records of 216 consecutive patients with NMIBC, who received BCG between 2010 and 2019, were reviewed. Kaplan-Meier curves and Cox proportional hazard regression were used for survival analysis. Results: We included 194 patients who underwent transurethral resection of a bladder tumour and received at least an induction course of BCG. The majority of patients presented with high-grade T1 tumours (n = 114, 59%). Within a median follow-up of 65 months (IQR: 27-93), 35 patients (18%) experienced progression, and 69 (34.5%) had a high-grade recurrence. Kaplan-Meier analyses revealed a significant association between higher MPVL and worse PFS and HG RFS (both p <0.05). Specifically, patients with higher MPVL demonstrated decreased 5-year PFS (75% vs 90%) and HG RFS (54.5% vs 75%) compared to lower MPVL counterparts. Multivariate analyses confirmed the independent prognostic value of MPVL for HG RFS (HR = 1.7, p = 0.047) and PFS (HR = 2.37, p = 0.026). Conclusions: In patients with NMIBC treated with adjuvant BCG, an elevated inflammatory marker comprising mean platelet volume and lymphocyte count ratio may serve as a prognostic factor associated with worse PFS and HG RFS. The role of MPVL in clinical decision-making must be validated in further multicentre prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.